The new drug approved by the FDA for polycythemia vera is Besremi.
Besremi: A New Treatment Option for Polycythemia Vera
Polycythemia vera is a blood disorder characterized by the overproduction of red blood cells. Previously, treatment options were limited. However, a new medication has been approved to help manage this condition.
According to the U.S. Food and Drug Administration (FDA), Besremi (ropeginterferon alfa-2b-njft) injection was approved on November 12, 2021, for treating adults with polycythemia vera.
| Drug Name | Generic Name | Indication | Approval Date |
|---|---|---|---|
| Besremi | Ropeginterferon alfa-2b-njft | Polycythemia Vera in Adults | November 12, 2021 |
This new drug offers another option for patients and healthcare providers in managing polycythemia vera.
